Reaktionsgleichung
[CH:1]12[CH2:7][CH:4]([CH2:5][CH2:6]1)[CH2:3][C@@H:2]2[NH:8][C:9]1[S:10][C:11]([CH2:16][CH:17]2[CH2:22][CH2:21][N:20]([C:23]([C:25]3[CH:26]=[C:27]([CH:39]=[CH:40][CH:41]=3)[O:28][CH2:29][CH2:30][NH:31][C:32](=[O:38])OC(C)(C)C)=[O:24])[CH2:19][CH2:18]2)([CH3:15])[C:12](=[O:14])[N:13]=1.NCCOC1C=[C:48]([CH:73]=[CH:74]C=1)[C:49](N1CCC(CC2(C)SC(N[C@H]3CC4CC3CC4)=NC2=O)CC1)=[O:50].O1C=CC(C(O)=O)=C1.CCN=C=NCCCN(C)C.C1C=CC2N(O)N=NC=2C=1.C(N(CC)CC)C>>[CH:1]12[CH2:7][CH:4]([CH2:5][CH2:6]1)[CH2:3][C@@H:2]2[NH:8][C:9]1[S:10][C:11]([CH2:16][CH:17]2[CH2:18][CH2:19][N:20]([C:23]([C:25]3[CH:26]=[C:27]([CH:39]=[CH:40][CH:41]=3)[O:28][CH2:29][CH2:30][NH:31][C:32]([C:73]3[CH:48]=[CH:49][O:50][CH:74]=3)=[O:38])=[O:24])[CH2:21][CH2:22]2)([CH3:15])[C:12](=[O:14])[N:13]=1Komponenten
7
Versuchsvorschrift
The title compound was prepared according to the procedure described in the preparation of tert-butyl 2-(3-(4-((2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carbonyl)phenoxy)ethylcarbamate by using 5-((1-(3-(2-aminoethoxy)benzoyl)piperidin-4-yl)methyl)-2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methylthiazol-4(5H)-one (93 mg, 0.19 mmol), 3-furoic acid (Aldrich, 39 mg, 0.35 mmol), EDCI (Aldrich, 74 mg, 0.38 mmol), HOBt (Aldrich, 5.2 mg, 0.038 mmol) and triethylamine (Aldrich, 39 mg, 0.38 mmol, 2.0 eq). The title compound was obtained as an off-white solid (89 mg). MS (ESI, pos. ion) m/z. 579 (M+H).
Aufarbeitung
- customThe title compound was prepared
Quellen und Nachweise
- ORD-Eintrag
- ord-7f250aae5c6e460f92c0e6dd52144c49
- Quelldatensatz
- uspto-grants-2013_09
- Patentnummer
- US08541592B2
Verknüpfte Notizen
Wird geladen…